Idenix Pharmaceuticals, Inc. (NASDAQ (GM): IDIX)
Cambridge, MA 02139 (Map) Phone: 617-995-9800
Fax: 617-995-9801
http://www.idenix.com
Overview
Idenix Pharmaceuticals is not suffering from any identity crisis -- it is clear in its focus on identifying treatments for life-threatening viruses. The biopharmaceutical firm is developing orally administered drugs to combat chronic hepatitis C (HCV) and HIV. Its lead HIV product candidate is in early clinical stages; its HCV candidates are in preclinical testing. Most are intended to be taken in combination with other therapeutic agents to improve efficacy and convenience. Under a development and commercialization agreement, Novartis has the option to license any of the product candidates developed by Idenix. Novartis owns 56% of Idenix.
Sample OverviewKey Numbers from Hoover's UK
Key financials for Idenix Pharmaceuticals, Inc. (NASDAQ (GM): IDIX)
| Company Type | Public (NASDAQ (GM): IDIX) |
|---|---|
| Fiscal Year-End | December |
| 2008 Sales (mil.) | £6.9 |
| 1-Year Sales Growth | (85.2%) |
| 2008 Net Income (mil.) | (£48.5) |
| 2008 Employees | 173 |
| 1-Year Employee Growth | (21.0%) |
Key People from Hoover's UK
Key people and executives for Idenix Pharmaceuticals, Inc. (NASDAQ (GM): IDIX)
| Chairman, President, and CEO | Jean-Pierre Sommadossi (Subscribers see complete biographies -- view sample)
Connect to this executive |
|---|---|
| CFO and Treasurer | Ronald C. (Ron) Renaud Jr. Connect to this executive |
| VP Corporate Communications | Amy Sullivan Connect to this executive |
Top Competitors from Hoover's UK
Top competitors of Idenix Pharmaceuticals, Inc. (NASDAQ (GM): IDIX)
There are 17 competitors for Idenix Pharmaceuticals; see more.
